Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae producing AmpC β-Lactamase.
- Author:
Ki Ho PARK
1
;
Yong Pil CHONG
;
Sung Han KIM
;
Sang Oh LEE
;
Mi Suk LEE
;
Heungsup SUNG
;
Mi Na KIM
;
Yang Soo KIM
;
Jun Hee WOO
;
Sang Ho CHOI
Author Information
- Publication Type:Brief Communication
- Keywords: Cephalosporin; Susceptibility; Enterobacteriaceae
- MeSH: Cefotaxime; Ceftazidime; Cephalosporins; Citrobacter freundii; Enterobacter; Enterobacteriaceae*; Morganella morganii; Phenotype; Serratia marcescens
- From:Infection and Chemotherapy 2017;49(1):62-67
- CountryRepublic of Korea
- Language:English
- Abstract: We evaluated the impact of revised Clinical and Laboratory Standards Institute (CLSI) breakpoints for broad-spectrum cephalosporins (BSCs) on the susceptibilities of 1,742 isolates of Enterobacter species, Serratia marcescens, Citrobacter freundii, and Morganella morganii. The 2011 CLSI criteria for cefotaxime and ceftazidime reduced the rates of susceptibility by 2.9% and 5.9%, respectively. The 2014 CLSI criteria for cefepime reduced the rate of susceptibility by 13.9%, and categorized 11.8% isolates as susceptible-dose dependent (SDD) for cefepime. Among 183 isolates with extended-spectrum ß-lactamase (ESBL) phenotype, implementation of the new criteria reduced the rates of susceptibility to cefotaxime, ceftazidime, and cefepime by 2.8%, 14.8%, and 53.6%, respectively. The proportion of ESBL phenotype among BSC-susceptible isolates was low (0.9% for cefotaxime, 3.0% for ceftazidime, and 3.3% for cefepime). In summary, implementation of new CLSI criteria led to little change in susceptibility to cefotaxime and ceftazidime but a substantial change in susceptibility to cefepime. The recognition of revised CLSI criteria for BSC and SDD will help clinicians to select the optimal antibiotic and dosing regimen.
